The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TIGIT IND FDA Clearance

19 Oct 2020 12:00

RNS Number : 4835C
Mereo BioPharma Group plc
19 October 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.

 

Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

 

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

 

Plans to host virtual R&D day to review etigilimab development program and rare disease product pipeline in November 2020

 

London and Redwood City, Calif., October 19, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) ("Mereo" or "the Company"), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application to proceed with a Phase 1b/2 study for the Company's lead oncology product candidate etigilimab. Etigilimab is a novel IgG1 monoclonal antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains), a next generation checkpoint receptor shown to block T-cell activation and the body's natural anti-cancer immune response.

 

Mereo is on track to initiate the Phase 1b/2 basket study in the fourth quarter of 2020. The study will evaluate etigilimab in combination with an anti-PD-1 initially in approximately 100 patients with a defined series of tumor types, including biomarker enriched and rare tumor cohorts. The study will incorporate flat dosing (for patients 50 kg and higher) which is based on data from Mereo's previous Phase 1a and Phase 1b combination studies with etigilimab. 

 

Dr. John Lewicki, Chief Scientific Officer of Mereo, said: "Recent clinical data regarding anti-TIGIT therapies in combination with PDL-1/PD-1 inhibition have been promising. We designed etigilimab as a novel IgG1 which blocks TIGIT signalling while retaining an intact effector function and we believe our development approach is differentiated. We have selected the tumor types for our planned Phase 1b/2 basket combination study based on biomarker screening of large collections of different tumor samples and correlating these with suboptimal responses to anti- PDL-1/PD-1. We've also included tumor types where we saw evidence of activity in our previous Phase 1a/1b study. We look forward to initiating the study this quarter and providing additional details during our planned virtual R&D day."

 

In November 2020, Mereo plans to host a virtual R&D day featuring external experts to review the etigilimab development program, including the design and biomarker strategy of the Phase 1b/2 basket combination study. Mereo also plans to provide an overview of its rare disease product pipeline. Further information including the date/time of the virtual R&D day will be announced in the coming weeks.

 

About Etigilimab

Etigilimab is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is a next generation checkpoint receptor shown to block T-cell activation and the body's natural anti-cancer immune response. Etigilimab is an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells with a goal of improving the activation and effectiveness of T-cell and NK cell anti-tumor activity. Mereo completed a Phase 1a dose escalation clinical trial with etigilimab in patients with advanced solid tumors and enrolled patients in a Phase 1b study in combination with nivolumab in selected tumor types.

 

23 patients were treated in the Phase 1a dose escalation study with doses up to 20 mg/kg Q2W. Tumor types included colorectal cancer, endometrial cancer, pancreatic cancer and other tumors. No dose limiting toxicities were observed. In the Phase 1b combination study, a total of ten patients, nine of whom had progressed on prior anti-PD-1/PD-L1 therapies were enrolled at doses of 3, 10, and 20 mg/kg. Eight patients were evaluable for tumor growth assessment, and all of these patients had progressed on PD-1/PD-L1 therapies with best responses including one patient with a partial response another with stable disease. These patients remained on study for up to 224 days. No dose limiting toxicities (DLTs) were observed and the most common related adverse events included fatigue, rash, and pruritis.

 

Mereo plans to initiate a Phase 1b/2 study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020.

 

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

 

Additional Information

The person responsible for arranging the release of this information on behalf of the Company is Charles Sermon, General Counsel.

 

Forward-Looking Statements

This Announcement contains "forward-looking statements." All statements other than statements of historical fact contained in this Announcement are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

 

All of the Company's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and involve assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. These forward-looking statements are subject to risks and uncertainties, including, among other things, those described in the Company's latest Annual Report on Form 20-F, Reports on Form 6-K and other documents filed from time to time by the Company with the United States Securities and Exchange Commission. The Company wishes to caution investors not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

 

Mereo BioPharma Contacts:

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer

N+1 Singer (Nominated Adviser and Broker to Mereo)

+44 (0)20 7496 3081

Phil Davies

Will Goode

Burns McClellan (US Investor Relations Adviser to Mereo)

+01 212 213 0006

Lisa Burns

Steve Klass

FTI Consulting (UK Public Relations Adviser to Mereo)

 +44 (0)20 3727 1000

Simon Conway

Ciara Martin

Investors

investors@mereobiopharma.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKKCBPCBDKAKD
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.